4B1F image
Deposition Date 2012-07-10
Release Date 2012-07-18
Last Version Date 2024-05-08
Entry Detail
PDB ID:
4B1F
Keywords:
Title:
Design of Inhibitors of Helicobacter pylori Glutamate Racemase as Selective Antibacterial Agents: Incorporation of Imidazoles onto a Core Pyrazolopyrimidinedione Scaffold to Improve Bioavailabilty
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.05 Å
R-Value Free:
0.23
R-Value Work:
0.18
R-Value Observed:
0.18
Space Group:
P 21 21 21
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:GLUTAMATE RACEMASE
Gene (Uniprot):murI
Chain IDs:A, B
Chain Length:255
Number of Molecules:2
Biological Source:HELICOBACTER PYLORI
Primary Citation
Design of Inhibitors of Helicobacter Pylori Glutamate Racemase as Selective Antibacterial Agents: Incorporation of Imidazoles Onto a Core Pyrazolopyrimidinedione Scaffold to Improve Bioavailabilty.
Bioorg.Med.Chem.Lett. 22 5600 ? (2012)
PMID: 22877632 DOI: 10.1016/J.BMCL.2012.07.004

Abstact

Structure-activity relationships are presented around a series of pyrazolopyrimidinediones that inhibit the growth of Helicobacter pylori by targeting glutamate racemase, an enzyme that provides d-glutamate for the construction of N-acetylglucosamine-N-acetylmuramic acid peptidoglycan subunits assimilated into the bacterial cell wall. Substituents on the inhibitor scaffold were varied to optimize target potency, antibacterial activity and in vivo pharmacokinetic stability. By incorporating an imidazole ring at the 7-position of scaffold, high target potency was achieved due to a hydrogen bonding network that occurs between the 3-position nitrogen atom, a bridging water molecule and the side chains Ser152 and Trp244 of the enzyme. The lipophilicity of the scaffold series proved important for expression of antibacterial activity. Clearances in vitro and in vivo were monitored to identify compounds with improved plasma stability. The basicity of the imidazole may contribute to increased aqueous solubility at lower pH allowing for improved oral bioavailability.

Legend

Protein

Chemical

Disease

Primary Citation of related structures